Literature DB >> 11854101

Palliative care in patients with multiple sclerosis.

A B Ben-Zacharia1, F D Lublin.   

Abstract

Multiple Sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system (CNS) and can be characterized by acute exacerbations or gradual worsening of neurological function and disability. The course of the disease is highly variable and unpredictable, however, there are short and long-term favorable and unfavorable predictive factors, which may provide some information about the future pattern of the disease. Palliative care in MS is directed at symptom management, psychosocial support, and rehabilitation. The goal in palliative care is to achieve a high quality of life. The disease modifying agents, interferon beta, Glatiramer acetate and Mitoxantrone are the mainstay of treatment in MS. Symptomatic relief and counseling of patients with MS have a strong impact on quality of life.

Entities:  

Mesh:

Year:  2001        PMID: 11854101     DOI: 10.1016/s0733-8619(05)70048-7

Source DB:  PubMed          Journal:  Neurol Clin        ISSN: 0733-8619            Impact factor:   3.806


  5 in total

1.  Palliative care for severely affected patients with multiple sclerosis: when and why? Results of a Delphi survey of health care professionals.

Authors:  Julia Strupp; Vanessa Romotzky; Maren Galushko; Heidrun Golla; Raymond Voltz
Journal:  J Palliat Med       Date:  2014-07-28       Impact factor: 2.947

Review 2.  [Quality of life in multiple sclerosis. Measures, relevance, problems, and perspectives].

Authors:  W Pöllmann; C Busch; R Voltz
Journal:  Nervenarzt       Date:  2005-02       Impact factor: 1.214

3.  The Role of Palliative Care in Chronic Progressive Neurological Diseases-A Survey Amongst Neurologists in the Netherlands.

Authors:  Hannah A W Walter; Antje A Seeber; Dick L Willems; Marianne de Visser
Journal:  Front Neurol       Date:  2019-01-14       Impact factor: 4.003

4.  Communication, Coordination, and Security for People with Multiple Sclerosis (COCOS-MS): a randomised phase II clinical trial protocol.

Authors:  Heidrun Golla; Kim Dillen; Martin Hellmich; Thomas Dojan; Solveig Ungeheuer; Petra Schmalz; Angelika Staß; Vanessa Mildenberger; Yasemin Goereci; Veronika Dunkl; Julia Strupp; Gereon R Fink; Raymond Voltz; Stephanie Stock; Oliver Cornely; Alexander Stahmann; Anne Müller; Peter Löcherbach; Lothar Burghaus; Volker Limmroth; Eckhard Bonmann; Kathrin Gerbershagen; Gereon Nelles; Thomas Joist; Judith Haas; Herbert Temmes; Clemens Warnke
Journal:  BMJ Open       Date:  2022-01-25       Impact factor: 2.692

5.  Unmet needs of people with severe multiple sclerosis and their carers: qualitative findings for a home-based intervention.

Authors:  Claudia Borreani; Elisabetta Bianchi; Erika Pietrolongo; Ilaria Rossi; Sabina Cilia; Miranda Giuntoli; Andrea Giordano; Paolo Confalonieri; Alessandra Lugaresi; Francesco Patti; Maria Grazia Grasso; Laura Lopes de Carvalho; Lucia Palmisano; Paola Zaratin; Mario Alberto Battaglia; Alessandra Solari
Journal:  PLoS One       Date:  2014-10-06       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.